Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 44, Issue 5, 2007, Pages 1139-1146

  DiFrancesco, Robin ^a   DiCenzo, Robert ^a   Vicente, Glorimar ^a   Donnelly, Julie ^a   Martin, Troy M ^b,c   Colon, Luis A ^a   Schifito, Giovanni ^d   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Clinton HIV/AIDS Initiative Vietnam   (Viet Nam)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Cerebral spinal fluid; Chromatography coupled to mass spectrometry; Lopinavir; Protein binding; Ultrafiltrate

Indexed keywords

ATAZANAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR;

ARTICLE; CALIBRATION; CEREBROSPINAL FLUID ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION;

ANTI-HIV AGENTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FREEZING; HUMANS; MOLECULAR STRUCTURE; PYRIMIDINONES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 34547740496     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.05.020     Document Type: Article

References (15)

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, October 10, 2006, Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, 2006.
2. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. N. Engl. J. Med. 338 (1998) 853-860
3. Boffito M., Hoggard P.G., Lindup W.E., Bonora S., Sinicco A., Khoo S.H., Di Perri G., and Back D.J. Ther. Drug Monit. 26 (2004) 35-39
4. Crommentuyn K.M., Huitema A.D., and Beijnen J.H. J. Pharm. Biomed. Anal. 38 (2005) 139-147
5. Ehrhardt M., Mock M., Haefeli W.E., Mikus G., and Burhenne J. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. (December 2006) (Epub ahead of print)
6. Wang P.G., Wei J.S., Kim G., Chang M., and El-Shourbagy T. J. Chromatogr. A 1130 (October 2006) 302-307
7. Capparelli E.V., Holland D., Okamoto C., Gragg B., Durelle J., Marquie-Beck J., van den Brande G., Ellis R., and Letendre S. Aids 19 (2005) 949-952
8. Isaac A., Taylor S., Cane P., Smit E., Gibbons S.E., White D.J., Drake S.M., Khoo S., and Back D.J. J. Antimicrob. Chemother. 54 (2004) 498-502
9. Keil K., Frerichs V.A., DiFrancesco R., and Morse G. Ther. Drug Monit. 25 (2003) 340-346
10. Stuart G. In: Gerfen C.R., Holmes A., Rogawski M.A., Sibley D.R., Sibley D., Skolnick P., and Wray S. (Eds). Current Protocols in Neuroscience (1998), Hoboken, NJ 6.7.5-6.7.6 Supplement 2
11. Barrail A., Le Tiec C., Paci-Bonaventure S., Furian V., Vincent I., and Taburet A.M. Ther. Drug Monit. 28 (2006) 89-94
12. Martin T.M., Morse G.D., Kurpewski J., Difrancesco R., Caliendo A.M., Flanigan T.P., and Tashima K.T. Aids 20 (2006) 1085-1087
13. Guidance for Industry Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, 2001.
14. Matuszewski B.K. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 830 (2006) 293-300
15. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 75 (2003) 3019-3030